CHINA’S food and drugs regulatory body has suspended its electronic drug monitoring system, a platform operated by Alibaba Health Information Technology Ltd., while it drafts amendments to regulations monitoring pharmaceutical sales.

    The China Food and Drug Administration (CFDA) said it will seek comments until March 23 on changes to the way pharmaceutical products are monitored, including online sales, according to statements posted on its website Saturday.

    Ali Health said in a filing yesterday it had not received notice from the CFDA over the operation of the platform.

    The suspension comes after Ali Health’s involvement in the platform, which allows consumers to check the authenticity of medical products online, was brought into the spotlight last month.

    Hunan-based pharmacy chain Yontinhe Group said last month it was suing the CFDA over the monitoring system, alleging the arrangement gave an unfair advantage to Ali Health, which has its own online drug sales business.

    Shares in Ali Health, an affiliate of e-commerce giant Alibaba Group Holding, fell sharply in the aftermath of the announcement, fuelled by concerns that the company could lose the right to run the platform, formally known as the Product Identification, Authentication and Tracking System (PIATS).

    Ali Health, whose shares dropped 14.29 percent yesterday, said it had not received notice from the CFDA to request that it discontinue providing technical support and maintenance services to the platform. (SD-Agencies)